Close
Help
Login
Staff Login
Register
FR
0
Selected
Invert selection
Deselect all
Deselect all
Add to Cart
Click here to refresh results
Click here to refresh results
Go to Login page
Hide details
Conceptually similar
CP121635062 | AstraZeneca vaccine to remain authorized in Canada
CP123262421 | N.S. pauses use of AstraZeneca vaccine
CP118971421 | AstraZeneca vaccine authorized in Canada
CP123251321 | Ontario to get more than 250,000 AstraZeneca doses
CP120124021 | AstraZeneca COVID-19 vaccine now recommended for Canadian seniors
CP121946460 | Newly eligible people receive Oxford-AstraZeneca vaccine
CP122017117 | AstraZeneca blood clot risk remains low: Tam
CP124342421 | Manitoba approves different second dose after AstraZeneca COVID-19 vaccine
CP118972171 | Newsroom Ready: AstraZeneca vaccine authorized in Canada
CP123597771 | Second-dose choice likely for AstraZeneca recipients: Tam
Placeline/People
City
Vaughan
Country
Canada
AstraZeneca vaccine's benefits vastly outweigh risks: Sharma
Health Canada's chief medical adviser Dr. Supriya Sharma says federal regulators are closely monitoring scientific findings about whether the Oxford-AstraZeneca vaccine against COVID-19 can lead to dangerous blood clots in a tiny percentage of recipients. But she says there's clear evidence the vaccine is extremely good at preventing COVID-19 and that vastly outweighs any potential risks.
Actions
Add to collection
Add to cart
Information
Source name:
The Canadian Press
Unique identifier:
CP120476771
Legacy Identifier:
n_COVID-Cda20210323T1400
Type:
Video
Duration:
1m47s
Dimensions:
1920px × 1080px 123.11 MB
Usage rights:
FOR ONE TIME USE ONLY. NO STORAGE FOR FUTURE USE.
Create Date:
3/23/2021 2:00:00 PM
Display aspect ratio:
16:9
Tags
AstraZeneca
Canada
canada government
Coronavirus
COVID-19
doses
health
Ontario
Ottawa
safety
vaccine
vaccines